{
  "symbol": "DLTR",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1594,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.135
  },
  "top_positive": [
    {
      "sent": "CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited) 13 Weeks Ended 26 Weeks Ended (in millions, except per share data) August 2, 2025 August 3, 2024 August 2, 2025 August 3, 2024 Net sales $ 4,566.8 $ 4,065.5 $ 9,203.3 $ 8,231.1 Other revenue 3.6 3.1 6.8 6.4 Total revenue 4,570.4 4,068.6 9,210.1 8,237.5 Cost of sales 2,996.7 2,674.2 5,983.7 5,363.3 Selling, general and administrative expenses 1,350.7 1,178.6 2,619.3 2,276.5 Transition services agreement income, net 8.0 \u2014 8.0 \u2014 Operating income 231.0 215.8 615.1 597.7 Interest expense, net 22.8 29.9 45.5 56.6 Other (income) expense, net ( 0.4 ) \u2014 ( 62.1 ) 0.1 Income from continuing operations before income taxes 208.6 185.9 631.7 541.0 Provision for income taxes 53.1 43.6 162.7 131.0 Income from continuing operations 155.5 142.3 469.0 410.0 Income (loss) from discontinued operations, net of tax 32.9 ( 9.9 ) 62.8 22.5 Net income $ 188.4 $ 132.4 $ 531.8 $ 432.5 Basic earnings (loss) per share of common stock: Continuing operations $ 0.75 $ 0.66 $ 2.23 $ 1.89 Discontinued operations 0.16 ( 0.04 ) 0.30 0.11 Total basic earnings per share of common stock $ 0.91 $ 0.62 $ 2.53 $ 2.00 Diluted earnings (loss) per share of common stock: Continuing operations $ 0.75 $ 0.66 $ 2.22 $ 1.89 Discontinued operations 0.16 ( 0.04 ) 0.30 0.11 Total diluted earnings per share of common stock $ 0.91 $ 0.62 $ 2.52 $ 2.00 Weighted average common shares outstanding: Basic 207.3 215.0 210.4 216.4 Diluted 207.8 215.2 210.8 216.7 See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.",
      "score": 0.9657
    },
    {
      "sent": "The following table presents our share repurchase activity during the second quarter of 2025: Fiscal Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions) May 4, 2025 - May 31, 2025 779,512 $ 86.61 779,512 $ 452.2 June 1, 2025 - July 5, 2025 3,198,258 97.78 3,198,258 139.5 July 6, 2025 - August 2, 2025 1,052,322 110.46 1,052,322 2,392.2 Total 5,030,092 $ 98.70 5,030,092 $ 2,392.2 In July 2025, our Board of Directors replenished the Company\u2019s share repurchase authorization to an aggregate amount of $2.5 billion, reflecting the limit previously approved by the Board in September 2021.",
      "score": 0.9432
    },
    {
      "sent": "The following table presents our share repurchase activity during the second quarter of 2025: Fiscal Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions) May 4, 2025 - May 31, 2025 779,512 $ 86.61 779,512 $ 452.2 June 1, 2025 - July 5, 2025 3,198,258 97.78 3,198,258 139.5 July 6, 2025 - August 2, 2025 1,052,322 110.46 1,052,322 2,392.2 Total 5,030,092 $ 98.70 5,030,092 $ 2,392.2 In July 2025, our Board of Directors replenished the Company\u2019s share repurchase authorization to an aggregate amount of $2.5 billion, reflecting the limit previously approved by the Board in September 2021.",
      "score": 0.9432
    }
  ],
  "top_negative": [
    {
      "sent": "Acetaminophen Matters Beginning in August 2022, more than 50 personal injury cases have been filed in federal court against Dollar Tree, Family Dollar, or both, on behalf of minors alleging that their mothers took acetaminophen while pregnant, that the acetaminophen interfered with fetal development such that plaintiffs were born with autism and/or ADHD, and that we knew or should have known of the danger, had a duty to warn and failed to include appropriate warnings on the product labels.",
      "score": -0.9001
    },
    {
      "sent": "Acetaminophen Matters Beginning in August 2022, more than 50 personal injury cases have been filed in federal court against Dollar Tree, Family Dollar, or both, on behalf of minors alleging that their mothers took acetaminophen while pregnant, that the acetaminophen interfered with fetal development such that plaintiffs were born with autism and/or ADHD, and that we knew or should have known of the danger, had a duty to warn and failed to include appropriate warnings on the product labels.",
      "score": -0.9001
    },
    {
      "sent": "The plaintiffs seek compensatory, punitive and exemplary damages, damages for loss of consortium, and attorneys\u2019 fees and costs.",
      "score": -0.886
    }
  ],
  "forward_snippets": [
    "We expect ASU 2023-09 to impact only our disclosures with no impact to our consolidated financial condition, results of operations, or cash flows.",
    "We will vigorously defend ourselves in these matters.",
    "We will vigorously defend ourselves in these matters.",
    "We believe that net sales per selling square foot more accurately depicts the productivity and operating performance of our stores as it reflects the portion of our footprint that is dedicated to selling merchandise.",
    "Strategic Initiatives and Recent Developments We continue to execute on a number of strategic initiatives to drive productive sales growth, improve operating efficiency, invest in technology, and expand our culture of service to our associates."
  ],
  "curated_text": "Symbol: DLTR. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited) 13 Weeks Ended 26 Weeks Ended (in millions, except per share data) August 2, 2025 August 3, 2024 August 2, 2025 August 3, 2024 Net sales $ 4,566.8 $ 4,065.5 $ 9,203.3 $ 8,231.1 Other revenue 3.6 3.1 6.8 6.4 Total revenue 4,570.4 4,068.6 9,210.1 8,237.5 Cost of sales 2,996.7 2,674.2 5,983.7 5,363.3 Selling, general and administrative expenses 1,350.7 1,178.6 2,619.3 2,276.5 Transition services agreement income, net 8.0 \u2014 8.0 \u2014 Operating income 231.0 215.8 615.1 597.7 Interest expense, net 22.8 29.9 45.5 56.6 Other (income) expense, net ( 0.4 ) \u2014 ( 62.1 ) 0.1 Income from continuing operations before income taxes 208.6 185.9 631.7 541.0 Provision for income taxes 53.1 43.6 162.7 131.0 Income from continuing operations 155.5 142.3 469.0 410.0 Income (loss) from discontinued operations, net of tax 32.9 ( 9.9 ) 62.8 22.5 Net income $ 188.4 $ 132.4 $ 531.8 $ 432.5 Basic earnings (loss) per share of common stock: Continuing operations $ 0.75 $ 0.66 $ 2.23 $ 1.89 Discontinued operations 0.16 ( 0.04 ) 0.30 0.11 Total basic earnings per share of common stock $ 0.91 $ 0.62 $ 2.53 $ 2.00 Diluted earnings (loss) per share of common stock: Continuing operations $ 0.75 $ 0.66 $ 2.22 $ 1.89 Discontinued operations 0.16 ( 0.04 ) 0.30 0.11 Total diluted earnings per share of common stock $ 0.91 $ 0.62 $ 2.52 $ 2.00 Weighted average common shares outstanding: Basic 207.3 215.0 210.4 216.4 Diluted 207.8 215.2 210.8 216.7 See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. The following table presents our share repurchase activity during the second quarter of 2025: Fiscal Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions) May 4, 2025 - May 31, 2025 779,512 $ 86.61 779,512 $ 452.2 June 1, 2025 - July 5, 2025 3,198,258 97.78 3,198,258 139.5 July 6, 2025 - August 2, 2025 1,052,322 110.46 1,052,322 2,392.2 Total 5,030,092 $ 98.70 5,030,092 $ 2,392.2 In July 2025, our Board of Directors replenished the Company\u2019s share repurchase authorization to an aggregate amount of $2.5 billion, reflecting the limit previously approved by the Board in September 2021. The following table presents our share repurchase activity during the second quarter of 2025: Fiscal Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions) May 4, 2025 - May 31, 2025 779,512 $ 86.61 779,512 $ 452.2 June 1, 2025 - July 5, 2025 3,198,258 97.78 3,198,258 139.5 July 6, 2025 - August 2, 2025 1,052,322 110.46 1,052,322 2,392.2 Total 5,030,092 $ 98.70 5,030,092 $ 2,392.2 In July 2025, our Board of Directors replenished the Company\u2019s share repurchase authorization to an aggregate amount of $2.5 billion, reflecting the limit previously approved by the Board in September 2021. Top negative sentences: Acetaminophen Matters Beginning in August 2022, more than 50 personal injury cases have been filed in federal court against Dollar Tree, Family Dollar, or both, on behalf of minors alleging that their mothers took acetaminophen while pregnant, that the acetaminophen interfered with fetal development such that plaintiffs were born with autism and/or ADHD, and that we knew or should have known of the danger, had a duty to warn and failed to include appropriate warnings on the product labels. Acetaminophen Matters Beginning in August 2022, more than 50 personal injury cases have been filed in federal court against Dollar Tree, Family Dollar, or both, on behalf of minors alleging that their mothers took acetaminophen while pregnant, that the acetaminophen interfered with fetal development such that plaintiffs were born with autism and/or ADHD, and that we knew or should have known of the danger, had a duty to warn and failed to include appropriate warnings on the product labels. The plaintiffs seek compensatory, punitive and exemplary damages, damages for loss of consortium, and attorneys\u2019 fees and costs. Forward-looking snippets: We expect ASU 2023-09 to impact only our disclosures with no impact to our consolidated financial condition, results of operations, or cash flows. We will vigorously defend ourselves in these matters. We will vigorously defend ourselves in these matters. We believe that net sales per selling square foot more accurately depicts the productivity and operating performance of our stores as it reflects the portion of our footprint that is dedicated to selling merchandise. Strategic Initiatives and Recent Developments We continue to execute on a number of strategic initiatives to drive productive sales growth, improve operating efficiency, invest in technology, and expand our culture of service to our associates."
}